Zinbryta risks outweigh benefits, European report

Multiple sclerosis treatment Zinbryta was withdrawn in March and now a review by the European Medicines Agency has found its risks outweigh its benefits. The review confirms the drug’s association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs. It was carried out by to the … Continue reading Zinbryta risks outweigh benefits, European report

MS drug Ocrevus could be barred from health service

Ocrevus may have taken the worldwide multiple sclerosis community by storm but it seems set for a rocky ride in the United Kingdom. It’s quite possible that it will not be available through the country’s National Health Service (NHS). Although the drug1, known by the non-brand name, ocrelizumab, was licensed by the European Medicines Agency … Continue reading MS drug Ocrevus could be barred from health service

MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders. That’s how the news was announced on the MS Society’s website. In the UK, the treatment will no longer be available via the country’s … Continue reading MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

Zinbryta use restricted in Europe after a death and four serious liver injuries

The European Medicines Agency (EMA) has restricted the use of multiple sclerosis drug Zinbryta. The agency took action after a patient died from liver injury (fulminant liver failure). The patient was in an ongoing observational study. Four cases of serious liver injury have also been reported. We are all likely to experience some side effect … Continue reading Zinbryta use restricted in Europe after a death and four serious liver injuries

European Medicines Agency recommends licence for cladribine (Mavenclad)

The European Medicines Agency has approved cladribine (brand name Mavenclad) for use with multiple sclerosis. The agency has recommended that a licence should be granted, by the European Commission, for the treatment of highly-active relapsing MS. Cladribine is currently an anti-cancer drug under the brand names Leustat and Litak. The next step in the process … Continue reading European Medicines Agency recommends licence for cladribine (Mavenclad)